Scribd
Upload
12 views3 pages

Noor Saba CBC Widal 13

Uploaded by

dt1546305
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
12 views3 pages

Noor Saba CBC Widal 13

Uploaded by

dt1546305
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 3

Patient Name : MRS.

NOOR SABA Patient ID : 42881


Age/Gender : 32 - Y / Female UHID :
Sample Id : 6735 Mobile No. : 7309696740
Ref. By : DR. D.K. TIWARI (BALDIRAI) Sample Date : 13-10-2024 12:15:PM
Center : DEHLI BAZAR BRANCH Reporting Date : 13-10-2024 01:00:PM

Test Description Result Unit Biological Reference Range

HAEMATOLOGY
Complete Blood Count (CBC)

HAEMOGLOBIN (HB) 12.4 g/dL 14.0-16.0


Method : Photometric Measurment
TOTAL LEUCOCYTE COUNT (TLC) 5050 cell/mm3 4000-11000
400Method: Impedance
Red Blood Cell Count (RBC 4.67 10^6/µl 3.80-4.80
Method: Impedance
Hematocrit (PCV) 37.20 % 36.0-46.0
Method: Calculated
Mean Corp Volume (MCV) 79.66 fL 83.0-101.0
Method: Derived from RBC Histogram
Mean Corp Hb (MCH) 26.55 pg 27.0-32.0
Method: Calculated
Mean Corp Hb Conc (MCHC) 33.33 g/dL 31.5-34.5
Method: Calculated
RDW - CV 16.0 % 11.6-14.0
Method: Derived from RBC Histogram
RDW - SD 54.4 fL 39.0-46.0
Method: Derived from RBC Histogram
Platelet Count (PLT) 115 10^3/µl 150-410
Method: Impedance

DIFFERNTIAL LEUCOCYTE COUNT

NEUTROPHILS 61.3 % 40 - 80
Method: VCS Technology
Lymphocytes 21.3 % 20-40
Monocytes 10.0 % 02 - 10
Method: VCS Technology
Eosinophils 7.40 % 01 - 06
Method: VCS Technology
BASOPHILS 0.00 % 0-1

Page - 1
Patient Name : MRS. NOOR SABA Patient ID : 42881
Age/Gender : 32 - Y / Female UHID :
Sample Id : 6735 Mobile No. : 7309696740
Ref. By : DR. D.K. TIWARI (BALDIRAI) Sample Date : 13-10-2024 12:15:PM
Center : DEHLI BAZAR BRANCH Reporting Date : 13-10-2024 01:00:PM

Test Description Result Unit Biological Reference Range


Method: VCS Technology

Absolute Leucocyte Count

Neutrophils (Abs Count) 309.56 /cu mm 200 - 700


Lymphocytes (Abs Count) 107.56 /cu mm 100 - 400
Eosinophils (Abs Count) 37.37 /cu mm 20 - 500
Monocytes (Abs Count) 50.50 /cu mm 20 - 100
Basophils (Abs Count) 0.00 /cu mm 20 - 50

SEROLOGY
WIDAL TEST

WIDAL SIGNIFICANT

Results 1:20 1:40 1:80 1:160 1:320 1:640


S.typhi-O + + + - - -
S.typhi-H + + + + - -
S.paratyphi A"H" + - - - - -
S.paratyphi B "H" - - - - - -

Interpretation: Titers 1:80 and above of O antigen and 1 :160 and above for H antigen are significant.
LIMITATIONS OF WIDAL TEST: 1.Numerous false positives due to cross reacting antibodies & heterospecific anamnestic responses, and false low titres as a
result of partial treatment are observed. This makes clinical correlation with lab findings mandatory. 2. Diagnostic titre is observed 7-10 days after the onset of fever.
In the first week of infection, the test is negative. 3. A rise in titre seen in two samples collected at a difference of one week is more significant.
The titter of the patient serum using Widal test antigen suspensions is the highest dilution of the serum sample that gives a visible agglutination.
The sample which shows the titre of 1:100 or more for O agglutinations and 1:200 or more for H agglutination should be considered as clinically significant (active
infection). Example: In the above figure, titter is 160.
Demonstration of 4-fold rise between the two is diagnostic.
H agglutination is more reliable than O agglutinin.
Agglutinin starts appearing in serum by the end of 1st week with sharp rise in 2nd and 3rd week and the titter remains steady till 4th week after which it declines.

Page - 2
Patient Name : MRS. NOOR SABA Patient ID : 42881
Age/Gender : 32 - Y / Female UHID :
Sample Id : 6735 Mobile No. : 7309696740
Ref. By : DR. D.K. TIWARI (BALDIRAI) Sample Date : 13-10-2024 12:15:PM
Center : DEHLI BAZAR BRANCH Reporting Date : 13-10-2024 01:00:PM

Test Description Result Unit Biological Reference Range

******** End of the report ********

Page - 3

You might also like